SES
24.2.2021 08:52:07 CET | Business Wire | Press release
SES Networks has announced today that it is working with Virgin Voyages to provide its fleet with the industry’s leading high-speed, low-latency connectivity. The ultra-modern Wi-Fi service will be free for every sailor. That’s pretty fly for Wi-Fi!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223006270/en/
Virgin Voyages’ Lady Ships will boast incredible speeds, unprecedented reliability, and all the bandwidth passengers could possibly need thanks to SES Networks’ satellite-enabled Signature Cruise Solution . Sailors on board the fleet will be able to stream their favourite HD movies, game online without lag, and seamlessly keep posting to the ‘gram while living for the moment and getting their full dose of Vitamin Sea.
"SES Networks offers us unique, reliable capabilities that rival land speed connectivity," said Andy Schwalb, Chief Marine & Technology Officer at Virgin Voyages. "This service has played a critical role in the success of our inaugural events last year, while also enabling our crew to remain connected and close to their loved ones during this challenging time. We know our Sailors will enjoy this service during their voyage as they document their vacation and share with others."
"It’s a delight to work with partners like Virgin Voyages who are raising the bar in the industry. They’re creating a sea change in the cruise market and high-speed connectivity is critical to realising their sky high ambitions,” said Simon Maher, Vice President Global Sales, Cruise Maritime Services at SES Networks. “Through our ultra-fast, low-latency connectivity, we’re able to empower Virgin Voyages’ sailors with Pretty Fly for a WiFi at sea that’s even faster than most home broadband.”
SES Networks’ Signature Cruise Solution is an end-to-end service that combines SES’s low-latency O3b satellite constellation, its upcoming next-generation O3b mPOWER system and its highly reliable geostationary (GEO) fleet to ensure seamless connectivity across the globe. Both O3b and O3b mPOWER systems are operating in the medium earth orbit, around 8,000km above earth’s surface.
The O3b mPOWER, when operational in 2022, will deliver significant increase of flexibility and throughput, and can deliver multiple gigabits per second to any Virgin Voyage ship sailing anywhere on earth during seasonal peaks and in areas of high density.
Follow us on:
Twitter
| Facebook
| YouTube
| LinkedIn
| Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Virgin Voyages
Virgin Voyages is a new lifestyle travel brand focused on delivering irresistible cruise vacations. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and across Europe. Virgin Voyages’ first ship, Scarlet Lady was designed to reflect a yacht’s sleek luxury, offering the intimate, elevated experience of a boutique hotel at sea. Featuring spaces designed by some of the top names in contemporary interiors, Scarlet Lady is Adult-by-Design and a sanctuary at sea for the 18+ traveler. A dose of Vitamin Sea will be naturally intertwined across the entire ship, with well-being, relaxation and rejuvenation at the forefront. Scarlet Lady will also feature alluring entertainment and 20+ world-class intimate eateries on board. With a modern twist on luxury, coupled with discerning design, Virgin Voyages offers incredible value for its sailors, including unlimited access to all restaurants and eateries, group fitness classes, free WiFi and tips covered in the voyage fare.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006270/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
